RU2017113827A - PHARMACEUTICAL COMPOSITION FOR REDUCING SPASES OF THE BLADDER AND METHOD OF ITS APPLICATION - Google Patents

PHARMACEUTICAL COMPOSITION FOR REDUCING SPASES OF THE BLADDER AND METHOD OF ITS APPLICATION Download PDF

Info

Publication number
RU2017113827A
RU2017113827A RU2017113827A RU2017113827A RU2017113827A RU 2017113827 A RU2017113827 A RU 2017113827A RU 2017113827 A RU2017113827 A RU 2017113827A RU 2017113827 A RU2017113827 A RU 2017113827A RU 2017113827 A RU2017113827 A RU 2017113827A
Authority
RU
Russia
Prior art keywords
inhibitor
prostaglandin
drug
pathway
formulated
Prior art date
Application number
RU2017113827A
Other languages
Russian (ru)
Other versions
RU2017113827A3 (en
Inventor
Дэвид А. ДИЛЛ
Original Assignee
УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of RU2017113827A publication Critical patent/RU2017113827A/en
Publication of RU2017113827A3 publication Critical patent/RU2017113827A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (18)

1. Применение композиции, включающей эффективное количество ацетаминофена и эффективное количество по меньшей мере одного нестероидного противовоспалительного лекарственного средства (НПВС), для получения лекарственного средства для уменьшения спазмов мочевого пузыря у субъекта.1. The use of a composition comprising an effective amount of acetaminophen and an effective amount of at least one non-steroidal anti-inflammatory drug (NSAID), to obtain a drug to reduce bladder spasms in a subject. 2. Применение по п. 1, где НПВС выбрано из группы, состоящей из аспирина, ибупрофена, напроксена натрия, напроксена, индометацина, набуметона, их солей и их комбинации.2. The use according to claim 1, where the NSAIDs are selected from the group consisting of aspirin, ibuprofen, naproxen sodium, naproxen, indomethacin, nabumetone, their salts and their combination. 3. Применение по п. 1 или 2, где НПВС представляет собой ибупрофен.3. The use of claim 1 or 2, wherein the NSAID is ibuprofen. 4. Применение по любому из пп. 1-3, где указанное лекарственное средство сформулировано для немедленного высвобождения, отсроченного высвобождения или пролонгированного высвобождения.4. The use according to any one of paragraphs. 1-3, where the specified drug is formulated for immediate release, delayed release or prolonged release. 5. Применение по любому из пп. 1-4, где указанное лекарственное средство сформулировано для перорального введения.5. The use according to any one of paragraphs. 1-4, where the specified drug is formulated for oral administration. 6. Применение по п. 5, где указанное лекарственное средство сформулировано в виде растворяющейся во рту лекарственной формы.6. The use according to claim 5, where the specified drug is formulated in the form of a dissolving in the mouth dosage form. 7. Применение по любому из пп. 1-5, где указанное лекарственное средство имеет энтеросолюбильное покрытие.7. The use according to any one of paragraphs. 1-5, where the specified drug is enteric coated. 8. Применение по любому из пп. 1-7, где указанная композиция дополнительно включает ингибитор PG пути, анальгетик, антимускариновое средство, антидиуретик, спазмолитическое средство, золпидем или их комбинацию.8. The use according to any one of paragraphs. 1-7, where the composition further includes a PG pathway inhibitor, analgesic, antimuscarinic agent, antidiuretic, antispasmodic agent, zolpidem, or a combination thereof. 9. Применение по п. 8, где ингибитор PG пути представляет собой ингибитор активности простагландина, ингибитор активности транспортера простагландина, ингибитор экспрессии транспортера простагландина, ингибитор активности рецептора простагландина или ингибитор экспрессии рецептора простагландина.9. The use of claim 8, wherein the PG pathway inhibitor is a prostaglandin activity inhibitor, a prostaglandin transporter activity inhibitor, a prostaglandin transporter expression inhibitor, a prostaglandin receptor activity inhibitor, or a prostaglandin receptor expression inhibitor. 10. Применение композиции, включающей эффективное количество ингибитора пути простагландина (PG) для получения лекарственного средства для уменьшения спазмов мочевого пузыря у субъекта, где ингибитор PG пути не является ацетаминофеном или НПВС.10. The use of a composition comprising an effective amount of a prostaglandin pathway inhibitor (PG) for the manufacture of a medicament for reducing bladder spasms in a subject where the PG pathway inhibitor is not acetaminophen or NSAIDs. 11. Применение по п. 10, где ингибитор PG пути представляет собой ингибитор активности простагландина, ингибитор активности транспортера простагландина, ингибитор экспрессии транспортера простагландина, ингибитор активности рецептора простагландина или ингибитор экспрессии рецептора простагландина.11. The use of claim 10, wherein the PG pathway inhibitor is a prostaglandin activity inhibitor, a prostaglandin transporter activity inhibitor, a prostaglandin transporter expression inhibitor, a prostaglandin receptor activity inhibitor, or a prostaglandin receptor expression inhibitor. 12. Применение по п. 10 или 11, где лекарственное средство сформулировано для немедленного высвобождения, отсроченного высвобождения или пролонгированного высвобождения.12. The use of claim 10 or 11, wherein the drug is formulated for immediate release, delayed release or extended release. 13. Фармацевтическая композиция для лечения спазмов мочевого пузыря, включающая:13. A pharmaceutical composition for treating bladder spasms, comprising: один или несколько ингибиторов PG пути; иone or more PG pathway inhibitors; and фармацевтически приемлемый носитель,a pharmaceutically acceptable carrier где один или несколько ингибиторов PG пути не включают ацетаминофен или НПВС.wherein one or more PG pathway inhibitors do not include acetaminophen or NSAIDs. 14. Фармацевтическая композиция по п. 13, где ингибитор PG пути представляет собой ингибитор активности простагландина, ингибитор активности транспортера простагландина, ингибитор экспрессии транспортера простагландина, ингибитор активности рецептора простагландина или ингибитор экспрессии рецептора простагландина.14. The pharmaceutical composition of claim 13, wherein the PG pathway inhibitor is a prostaglandin activity inhibitor, a prostaglandin transporter activity inhibitor, a prostaglandin transporter expression inhibitor, a prostaglandin receptor activity inhibitor, or a prostaglandin receptor expression inhibitor. 15. Фармацевтическая композиция по п. 13 или 14, где лекарственное средство сформулировано для немедленного высвобождения, отсроченного высвобождения или пролонгированного высвобождения.15. The pharmaceutical composition according to p. 13 or 14, where the drug is formulated for immediate release, delayed release or prolonged release.
RU2017113827A 2014-09-24 2014-09-24 PHARMACEUTICAL COMPOSITION FOR REDUCING SPASES OF THE BLADDER AND METHOD OF ITS APPLICATION RU2017113827A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/057200 WO2016048301A1 (en) 2014-09-24 2014-09-24 Pharmaceutical formulation for reducing bladder spasms and method of use thereof

Publications (2)

Publication Number Publication Date
RU2017113827A true RU2017113827A (en) 2018-10-24
RU2017113827A3 RU2017113827A3 (en) 2018-10-24

Family

ID=55581626

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017113827A RU2017113827A (en) 2014-09-24 2014-09-24 PHARMACEUTICAL COMPOSITION FOR REDUCING SPASES OF THE BLADDER AND METHOD OF ITS APPLICATION

Country Status (13)

Country Link
EP (1) EP3197441A4 (en)
JP (1) JP2017532301A (en)
KR (1) KR20170049613A (en)
CN (1) CN107072971A (en)
AU (1) AU2014407186A1 (en)
BR (1) BR112017006141A2 (en)
CA (1) CA2962004A1 (en)
IL (1) IL250827A0 (en)
MX (1) MX2017003878A (en)
RU (1) RU2017113827A (en)
SG (1) SG11201702069XA (en)
WO (1) WO2016048301A1 (en)
ZA (1) ZA201701772B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7025129B2 (en) * 2017-05-17 2022-02-24 小林製薬株式会社 Muscle spasm remedy
WO2019240755A1 (en) * 2018-06-11 2019-12-19 Wellesley Pharmaceuticals, Llc Pharmaceutical compositions and methods for weight loss

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328060D0 (en) * 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
EP1881821B1 (en) * 2005-05-20 2016-11-09 Omeros Corporation Compositions comprising ketoprofen and calcium channel antagonist for use in urological procedures
CN101460150B (en) * 2006-03-31 2014-02-12 鲁比康研究私人有限公司 Directly compressible composite for orally disintegrating tablets
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction
BR112013019410A2 (en) * 2011-02-04 2019-09-24 Taris Biomedical Inc implantable device for controlled release of low solubility drug
KR20140108675A (en) * 2012-01-04 2014-09-12 웰즐리 파마슈티컬스 엘엘씨 Extended-release formulation for reducing the frequency of urination and method of use thereof
CN103191430A (en) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 Sustained release preparation for relieving frequent micturition and application method thereof

Also Published As

Publication number Publication date
AU2014407186A1 (en) 2017-03-09
EP3197441A1 (en) 2017-08-02
CA2962004A1 (en) 2016-03-31
SG11201702069XA (en) 2017-04-27
ZA201701772B (en) 2018-08-29
BR112017006141A2 (en) 2018-02-06
MX2017003878A (en) 2017-06-28
WO2016048301A1 (en) 2016-03-31
RU2017113827A3 (en) 2018-10-24
CN107072971A (en) 2017-08-18
IL250827A0 (en) 2017-04-30
JP2017532301A (en) 2017-11-02
KR20170049613A (en) 2017-05-10
EP3197441A4 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
AR122580A2 (en) DOSAGE FORM OF DOXYLAMINE AND PYRIDOXINE AND/OR THEIR METABOLITES OR SALTS
MA32692B1 (en) METHOD FOR RELEASING A PHARMACEUTICAL COMPOSITION FROM A PATIENT THAT NEEDS
JP2015503583A5 (en)
HRP20150644T1 (en) Method of treating atrial fibrillation
JP2014526503A5 (en)
JP2015512406A5 (en)
RU2016133305A (en) COMPOSITION WITH LONG-TERM RELEASE TO REDUCE THE URINE FREQUENCY AND METHOD OF ITS APPLICATION
JP2015038135A5 (en)
HRP20230267T1 (en) Compositions for the treatment of hypertension
BR112014014795A2 (en) immediate release multi-unit pellet system
JP2013517304A5 (en)
JP2015522659A5 (en)
JP2015522658A5 (en)
RU2017113827A (en) PHARMACEUTICAL COMPOSITION FOR REDUCING SPASES OF THE BLADDER AND METHOD OF ITS APPLICATION
RU2015106672A (en) PHARMACEUTICAL COMPOSITION FOR REDUCING THE URINE FREQUENCY AND METHOD OF ITS APPLICATION
RU2016152226A (en) Pharmaceutical composition for reducing the frequency of urination and method for its use
RU2016148182A (en) (R) -PYRLINDOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
MX2013001279A (en) Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form.
CO2018009543A2 (en) Extended release pharmaceutical composition comprising cysteamine or salt thereof
RU2019102890A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING FLURBIPROPHEN
JP2012041314A5 (en)
JP2011525479A5 (en)
MX2018003890A (en) Pharmaceutical compositions containing a muscle relaxant and a non-steroidal anti-inflammatory drug (nsaid).
AR063228A1 (en) NON-STEROID ANTINFLAMATORIES AGAINST TOS
AR081007A1 (en) CHARACTERIZED PHARMACEUTICAL COMBINATION BECAUSE IT INCLUDES IBUPROFEN AND L-ARGININA

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191021